DNAJC30

Across TCGA pan-cancer cohorts, DNAJC30 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DNAJC30 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DNAJC30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJC30 expression acts as an unfavorable survival marker.

BLCA and LUSC are the cancer types where DNAJC30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.687	.003	18	view →
LUSC	OS	Median	All	0.152	0.762	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

DNAJC30–BLCA (OS)

Open the BLCA breakdown →